Immunai
Immunai is a biotech company that combines single cell genomics with ML algorithms to enable high resolution profiling of the immune system.
Immunai has raised €18M across 1 funding round from 2 investors, most recently a Seed round in May 2020. Based in New York, United States; founded 2019; active in AI. Data as of 28 Oct 2026.
Total raised
€18M
€18,390,805
Funding rounds
1
Investors
2
distinct backers
Active since
2020-05
latest 2020-05
Funding by year
EUR raised per yearImmunai — funding by year — interactive chart.
Data table
| Immunai — funding by year | |
|---|---|
| 2020 | €18M |
Signals
High confidenceRaise-next likelihood8
base rate 44% for Seed
- ▼ Dormant (no round in 3+ cohort gaps)
- ▼ Low backer re-investment
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
1 round| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2020-05-14 | Seed | €18M | TLV Partners,Viola Ventures | View deal → |
Investors
2Related news
Similar companies
same sector or country- Mistral AI€6.5BFrance · AI
- Helsing€2.9BGermany · AI
- UiPath€1.7BRomania · AI
- ElevenLabs€1.2BUK · AI
- Ineffable Intelligence€936MUK · AI
- Advanced Machine Intelligence (AMI)€885MFrance · AI
Global coverage: FundingData